Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the use of oral versus topical minoxidil for hairline recession, with concerns about collagen synthesis inhibition. Oral minoxidil may affect collagen production more broadly, while topical minoxidil's effects are localized but may cause skin issues.

Using pp405 on transplanted hair might increase density or cause folliculitis, but its effects are uncertain since pp405 is not yet available. Transplantation may damage some follicles, but most original dormant hair could still grow.

The user is experiencing hair improvement in the central and back areas after using finasteride, minoxidil, and a galenic lotion, but the temple area is worsening. They suspect the lotion might be causing the issue and are considering stopping its use.

Finasteride and minoxidil treatments plateaued after 10 months, leading users to explore additional options like microneedling and low-level laser therapy (LLT) caps, though many are skeptical of the effectiveness and marketing of LLT devices like Kiierr. Users express frustration with the lack of clear recommendations from dermatologists and the prevalence of marketing hype over genuine reviews.

The user experienced hairline improvement using microneedling once a month with a 12-pin set at 1.5-2.0mm and taking Tru Niagen, alongside a heavily modified diet. They attribute the slow hairline improvement to environmental factors, particularly diet, rather than solely genetic factors.

The conversation humorously discusses the idea of cloning oneself for hair transplants, with suggestions of lobotomizing and castrating the clone. It includes various satirical and absurd comments about using clones for personal benefits beyond hair, such as companionship and organ donation.

A 37-year-old is starting 0.5mg finasteride to address diffuse hair thinning, with support from a dermatologist. They also use DS Labs shampoo and micro-needle every two weeks.

Lichen Planopilaris (LPP) is an autoimmune condition causing permanent hair loss and fibrosis, often misdiagnosed. Treatments include pioglitazone, topical corticosteroids, anti-inflammatory medication, and Jak inhibitors.

The user has been using topical minoxidil for over a year and added kx826/pyrilutamide to improve hair growth, avoiding finasteride due to side effects like lowered libido and panic attacks. They report positive results with reduced shedding and healthier hair, particularly in areas previously unresponsive to minoxidil.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

A user shared their positive experience with a hair transplant in Turkey using the DHI and Sapphire FUE techniques, without taking finasteride or minoxidil post-surgery. They emphasized that transplanted hairs from the donor area are resistant to hair loss, but acknowledged that native hairs might still thin without medication.

The user has been using liposomal topical finasteride since late 2022, progressively increasing the dose, but DHT serum levels remain largely unchanged. Despite using finasteride, minoxidil, microneedling, and ketoconazole, hair condition has neither improved nor worsened.

The user has been using a combination spray with 0.1% finasteride, 5% minoxidil, and tretinoin for over a year but feels their hairline has worsened. They are considering increasing the concentration of finasteride and adding 5% minoxidil once a day, while another user suggests trying oral finasteride for potentially better results.

Hair regrowth using finasteride 1mg daily and topical minoxidil twice daily, with a hair transplant after three years, showed significant improvement over four years. The user is satisfied with the results despite not having access to oral minoxidil.

A user is considering using melatonin for hair recovery on the side and neck area but is unsure about the best options in Europe and whether a dietary supplement form can be applied to the scalp. They found a product but are hesitant and seeking opinions on its use for alopecia.

A 35-year-old male experiences rapid hair loss on his head and body despite normal test results for testosterone, thyroid, and vitamins. He previously used topical minoxidil and retinol, and doctors have been consulted without finding a clear cause.

Stopping hair loss treatments like finasteride and minoxidil can result in losing regrown hair, highlighting the importance of consistent use. Restarting these treatments may cause temporary shedding, but hair can regrow with continued use.

Low-Level Laser Therapy (LLLT) is considered expensive and may not provide significant benefits, with some users suggesting alternatives like finasteride, minoxidil, and microneedling. Many users report limited success with LLLT and similar treatments, recommending more proven options instead.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

Switching from topical to oral minoxidil led to hair thinning and loss of baby hairs, likely due to a shedding phase. Users suggest this is common and may improve by the six-month mark.

Stemson's presentation discussed using induced pluripotent stem cell technology to create new hair follicles for treating hair loss. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.

The user increased their steroid dosage and noticed hair shedding, so they adjusted their regimen by reducing steroid doses and adding oral dutasteride. They are also experimenting with combining RU-58841 and KX-826/pyrilutamide in minoxidil to address hair loss.

A quercetin-encapsulated and polydopamine-integrated nanosystem (PDA@QLipo) shows promise for treating androgenetic alopecia by reshaping the perifollicular microenvironment, outperforming minoxidil in hair regeneration. The nanosystem promotes cell proliferation, hair follicle renewal, and recovery by scavenging reactive oxygen species and enhancing neovascularity.

A 37-year-old man reports significant hair regrowth using a regimen of topical minoxidil, oral finasteride, derma rolling, and saw palmetto shampoo, but notices uneven progress between the sides of his head. He theorizes that sleeping on one side might affect hair growth, but others suggest it could be unrelated to sleeping habits.

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

The conversation discusses the delay in the release of GT20029 for hair loss treatment and skepticism about its effectiveness. Participants mention other treatments like verteporfin and advancements in transplant procedures as more realistic options.

The user has been using finasteride and topical minoxidil for 15 months but is experiencing constant hair shedding, similar to telogen effluvium, despite stable widow peaks. They have checked for vitamin and mineral deficiencies, consulted specialists, and are considering further investigation like a scalp biopsy.

The conversation discusses hair loss treatments, specifically the use of finasteride (Fin) and oral minoxidil (Oral Min), with progress shown using hair fibers like DermMatch and Toppik. The original poster plans a hair transplant and mentions side effects like reduced libido from finasteride.

CB-03-01 is considered a failed treatment for hair loss, with future hopes pinned on PP-405 and GT-20029, expected by 2030. Alternatives like hair transplants and SMP are discussed, while some users express frustration over the slow progress of treatments like Breezula.

A 19-year-old used a 0.01% topical finasteride formula, which unexpectedly lowered DHT levels significantly. They are considering reducing the dose further and exploring alternatives like ketoconazole shampoo, KX826, and CB to manage hair loss while minimizing systemic absorption.